ReviewTherapeutic advances in psychopharmacology2014
Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports.
Review in Therapeutic advances in psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 65 citations in OpenAlex.
- Molecular Mechanisms of Acute Drug Toxicity in Polypharmacy: Analgesic-Psychotropic Interactions.International journal of molecular sciences · 2026Review
- Article
- Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses.Frontiers in pharmacology · 2026Article
- The Role of Quetiapine in Treating Delirium in Critical Care Settings: A Narrative Review.Journal of clinical medicine · 2025Review
- Acute Quetiapine Intoxication: Relationship Between Ingested Dose, Serum Concentration and Clinical Presentation-Structured Literature Review and Analysis.Journal of xenobiotics · 2024Review
- Central Pontine Myelinolysis: A Rare and Life-Threatening Adverse Effect of Clobazam and Quetiapine.Cureus · 2024Article
- Predictors for prolonged qt intervals in acute antipsychotic poisoned patients.Toxicology research · 2024Article
- Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.European archives of psychiatry and clinical neuroscience · 2023Article
- Prevalence and risk factors for acquired long QT syndrome in the emergency department: a retrospective observational study.World journal of emergency medicine · 2023Article
- Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia.International journal of molecular sciences · 2022Review
- Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report.BMC psychiatry · 2022Article
- Sex-Specific Classification of Drug-Induced Torsade de Pointes Susceptibility Using Cardiac Simulations and Machine Learning.Clinical pharmacology and therapeutics · 2021Article
- QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson's Disease Psychosis: A Narrative Review.Neuropsychiatric disease and treatment · 2021Review
- Comparison of Antipsychotics for the Treatment of Patients With Delirium and QTc Interval Prolongation: A Clinical Decision Analysis.Frontiers in psychiatry · 2021Article
- Cytochrome P450 (CYP450) Interactions Involving Atypical Antipsychotics are Common in Community-Dwelling Older Adults Treated for Behavioral and Psychological Symptoms of Dementia.Pharmacy (Basel, Switzerland) · 2020Article
- Quetiapine and Wolff-Parkinson-White Syndrome.Case reports in psychiatry · 2020Article
- QT interval prolongation andTherapeutic advances in drug safety · 2020Article
- Chronic Post-stroke Psychosis with Left Cortical and Bilateral Inferior Cerebellar Involvement.Cureus · 2019Article
- Donepezil-induced QTc prolongation: A case report.The mental health clinician · 2019Article
- Ventricular fibrillation due to overdose of loperamide, the "poor man's methadone".Journal of community hospital internal medicine perspectives · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, both the manufacturer of quetiapine and the US Food and Drug Administration warned healthcare providers and patients about quetiapine-induced QTc interval prolongation and torsade de pointes (TdP) when using this drug within the approved labeling. We reviewed the case-report literature and found 12 case reports of QTc interval prolongation in the setting of quetiapine administration. There were no cases of quetiapine-induced TdP or sudden cardiac death (SCD) among patients using quetiapine appropriately and free of additional risk factors for QTc interval prolongation and TdP. Among the 12 case reports risk factors included female sex (nine cases), coadministration of a drug associated with QTc interval prolongation (eight cases), hypokalemia or hypomagnesemia (six cases) quetiapine overdose (five cases), cardiac problems (four cases), and coadministration of cytochrome P450 3A4 inhibitors (two cases). There were four cases of TdP. As drug-induced TdP is a rare event, prospective studies to evaluate the risk factors associated with QTc prolongation and TdP are difficult to design, would be very costly, and would require very large samples to capture TdP rather than its surrogate markers. Furthermore, conventional statistical methods may not apply to studies of TdP, which is rare and an 'outlier' manifestation of QTc prolongation. We urge drug manufacturers and regulatory agencies to periodically publish full case reports of psychotropic drug-induced QTc interval prolongation, TdP, and SCD so that clinicians and investigators may better understand the clinical implications of prescribing such drugs as quetiapine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.